157 related articles for article (PubMed ID: 19015953)
21. Transient rise in serum soluble Fas (APO-1/CD95) in patients undergoing cardiac surgery.
Kawahito K; Misawa Y; Fuse K
Artif Organs; 2000 Aug; 24(8):628-31. PubMed ID: 10971250
[TBL] [Abstract][Full Text] [Related]
22. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer.
Yildiz R; Benekli M; Buyukberber S; Kaya AO; Ozturk B; Yaman E; Berk V; Coskun U; Yamac D; Sancak B; Uner A
J Cancer Res Clin Oncol; 2010 Oct; 136(10):1471-6. PubMed ID: 20155284
[TBL] [Abstract][Full Text] [Related]
23. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
[TBL] [Abstract][Full Text] [Related]
24. The value of S-phase and DNA ploidy analysis as prognostic markers for node-negative breast cancer in the Australian setting.
Wong SW; Rangan AM; Bilous AM; Boyages J; Gebski V; Benson EM
Pathology; 1999 May; 31(2):90-4. PubMed ID: 10399161
[TBL] [Abstract][Full Text] [Related]
25. [Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer].
Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
Cancer Radiother; 2005 Dec; 9(8):575-86. PubMed ID: 16243560
[TBL] [Abstract][Full Text] [Related]
26. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients.
Papathanassoglou ED; Moynihan JA; Vermillion DL; McDermott MP; Ackerman MH
Shock; 2000 Aug; 14(2):107-12. PubMed ID: 10947151
[TBL] [Abstract][Full Text] [Related]
27. Soluble Fas in serum from patients with renal cell carcinoma.
Nonomura N; Nishimura K; Ono Y; Fukui T; Harada Y; Takaha N; Takahara S; Okuyama A
Urology; 2000 Jan; 55(1):151-5. PubMed ID: 10654915
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma.
Jodo S; Kobayashi S; Nakajima Y; Matsunaga T; Nakayama N; Ogura N; Kayagaki N; Okumura K; Koike T
Clin Exp Immunol; 1998 May; 112(2):166-71. PubMed ID: 9649177
[TBL] [Abstract][Full Text] [Related]
29. Circulating soluble Fas in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
[TBL] [Abstract][Full Text] [Related]
30. [Expression of FAS-AS1 in breast cancer and its effect on the host gene sFas].
Zhou SW; Su BB; Zhou Y
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):949-53. PubMed ID: 27045720
[TBL] [Abstract][Full Text] [Related]
31. Short-term significance of DNA ploidy and cell proliferation in breast carcinoma: a multivariate analysis of prognostic markers in a series of 308 patients.
Pinto AE; André S; Soares J
J Clin Pathol; 1999 Aug; 52(8):604-11. PubMed ID: 10645231
[TBL] [Abstract][Full Text] [Related]
32. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
Pinto AE; André S; Pereira T; Silva G; Soares J
Pathobiology; 2006; 73(2):63-70. PubMed ID: 16943686
[TBL] [Abstract][Full Text] [Related]
33. A high serum soluble Fas/APO-1 level is associated with a poor outcome of aggressive non-Hodgkin's lymphoma.
Niitsu N; Sasaki K; Umeda M
Leukemia; 1999 Sep; 13(9):1434-40. PubMed ID: 10482996
[TBL] [Abstract][Full Text] [Related]
34. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape.
Bernstorff WV; Glickman JN; Odze RD; Farraye FA; Joo HG; Goedegebuure PS; Eberlein TJ
Cancer; 2002 May; 94(10):2552-60. PubMed ID: 12173320
[TBL] [Abstract][Full Text] [Related]
35. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
36. Prognostic values of KAI1 and survivin expression in an infiltrating ductal carcinoma of the breast.
Son BH; Choi JS; Lee JH
Pathology; 2005 Apr; 37(2):131-6. PubMed ID: 16028840
[TBL] [Abstract][Full Text] [Related]
37. [Proliferation index and its prognostic value in invasive ductal breast carcinoma].
Falco M
Ann Acad Med Stetin; 2009; 55(1):22-30. PubMed ID: 20349588
[TBL] [Abstract][Full Text] [Related]
38. Apoptosis markers soluble Fas (sFas), Fas Ligand (FasL) and sFas/FasL ratio in patients with bacteremia: a prospective cohort study.
Huttunen R; Syrjänen J; Vuento R; Laine J; Hurme M; Aittoniemi J
J Infect; 2012 Mar; 64(3):276-81. PubMed ID: 22207003
[TBL] [Abstract][Full Text] [Related]
39. Examination of soluble Fas (sFas) and soluble Fas ligand (sFasL) in patients with burns.
Yamada Y; Endo S; Nakae H; Makabe H; Sato N; Wakabayashi G; Kitamura M; Inada K; Sato S
Burns; 2003 Dec; 29(8):799-802. PubMed ID: 14636754
[TBL] [Abstract][Full Text] [Related]
40. The clinical significance of serum soluble Fas and p53 protein in breast cancer patients: comparison with serum CA 15-3.
Hewala TI; Abd El-Monaim NA; Anwar M; Ebied SA
Pathol Oncol Res; 2012 Oct; 18(4):841-8. PubMed ID: 22422199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]